Bioengineered Lysozyme Reduces Bacterial Burden and Inflammation in a Murine Model of Mucoid Pseudomonas aeruginosa Lung Infection
Antimicrobial Agents and Chemotherapy
Thayer School of Engineering
The spread of drug-resistant bacterial pathogens is a growing global concern and has prompted an effort to explore potential adjuvant and alternative therapies derived from nature's repertoire of bactericidal proteins and peptides. In humans, the airway surface liquid layer is a rich source of antibiotics, and lysozyme represents one of the most abundant and effective antimicrobial components of airway secretions. Human lysozyme is active against both Gram-positive and Gram-negative bacteria, ac
Teneback CC, Scanlon TC, Wargo MJ, Bement JL, Griswold KE, Leclair LW. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother. 2013 Nov;57(11):5559-64. doi: 10.1128/AAC.00500-13. Epub 2013 Aug 26. PMID: 23979752; PMCID: PMC3811238.
Dartmouth Digital Commons Citation
Teneback, Charlotte C.; Scanlon, Thomas C.; Wargo, Matthew J.; Bement, Jenna L.; Griswold, Karl E.; and Leclair, Laurie W., "Bioengineered Lysozyme Reduces Bacterial Burden and Inflammation in a Murine Model of Mucoid Pseudomonas aeruginosa Lung Infection" (2013). Dartmouth Scholarship. 468.
Animal Sciences Commons, Bacterial Infections and Mycoses Commons, Biochemistry Commons, Respiratory System Commons